KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EPS (Weighted Average and Diluted) (2016 - 2025)

Supernus Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 15 years, most recently at -$0.07 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 125.93% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.68 through Dec 2025, down 151.52% year-over-year, with the annual reading at -$0.68 for FY2025, 151.52% down from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.07 for Q4 2025 at Supernus Pharmaceuticals, up from -$0.8 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.69 in Q3 2024 and troughed at -$0.8 in Q3 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.12 (2021), against an average of $0.13.
  • Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 1900.0% in 2024 and then tumbled 8268.95% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.04 in 2021, then soared by 950.0% to $0.42 in 2022, then crashed by 95.24% to $0.02 in 2023, then soared by 1250.0% to $0.27 in 2024, then crashed by 125.93% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's EPS (Weighted Average and Diluted) are -$0.07 (Q4 2025), -$0.8 (Q3 2025), and $0.4 (Q2 2025).